Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia

A follow-up of the Eastern Cooperative Oncology Group E3A98 trial

Morie A. Gertz, Rafat Abonour, Leonard T. Heffner, Philip R. Greipp, Hajime Uno, S. V. Rajkumar

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Waldenström macroglobulinaemia is a low-grade, lymphoplasmacytic lymphoma that is responsive to rituximab. We report the role of a minor response in predicting overall outcomes. We extended follow-up of a previously described cohort (n = 69) treated with 4 weekly doses of rituximab and observed durable responses (median time to progression, 30 months; 5-year survival rate, 66%). Patients achieving a minor response [25-50% immunoglobulin M (IgM) reduction] appeared to do as well as those achieving an objective response (>50% IgM reduction), which suggests that more aggressive or intensive therapy for minor responders is not required. Future studies of Waldenström macroglobulinaemia should report minor responses because they are associated with clinically meaningful benefits. This trial was registered at http://www.clinicaltrials.gov as #NCT00005609.

Original languageEnglish
Pages (from-to)677-680
Number of pages4
JournalBritish Journal of Haematology
Volume147
Issue number5
DOIs
StatePublished - Dec 2009

Fingerprint

Waldenstrom Macroglobulinemia
Immunoglobulin M
Non-Hodgkin's Lymphoma
Survival Rate
Rituximab
Therapeutics

Keywords

  • Lymphoplasmacytic lymphoma
  • Monoclonal IgM protein
  • Rituximab
  • Waldenström macroglobulinaemia

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia : A follow-up of the Eastern Cooperative Oncology Group E3A98 trial. / Gertz, Morie A.; Abonour, Rafat; Heffner, Leonard T.; Greipp, Philip R.; Uno, Hajime; Rajkumar, S. V.

In: British Journal of Haematology, Vol. 147, No. 5, 12.2009, p. 677-680.

Research output: Contribution to journalArticle

@article{fc72dad8322b40c78376ece9b4118c79,
title = "Clinical value of minor responses after 4 doses of rituximab in Waldenstr{\"o}m macroglobulinaemia: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial",
abstract = "Waldenstr{\"o}m macroglobulinaemia is a low-grade, lymphoplasmacytic lymphoma that is responsive to rituximab. We report the role of a minor response in predicting overall outcomes. We extended follow-up of a previously described cohort (n = 69) treated with 4 weekly doses of rituximab and observed durable responses (median time to progression, 30 months; 5-year survival rate, 66{\%}). Patients achieving a minor response [25-50{\%} immunoglobulin M (IgM) reduction] appeared to do as well as those achieving an objective response (>50{\%} IgM reduction), which suggests that more aggressive or intensive therapy for minor responders is not required. Future studies of Waldenstr{\"o}m macroglobulinaemia should report minor responses because they are associated with clinically meaningful benefits. This trial was registered at http://www.clinicaltrials.gov as #NCT00005609.",
keywords = "Lymphoplasmacytic lymphoma, Monoclonal IgM protein, Rituximab, Waldenstr{\"o}m macroglobulinaemia",
author = "Gertz, {Morie A.} and Rafat Abonour and Heffner, {Leonard T.} and Greipp, {Philip R.} and Hajime Uno and Rajkumar, {S. V.}",
year = "2009",
month = "12",
doi = "10.1111/j.1365-2141.2009.07892.x",
language = "English",
volume = "147",
pages = "677--680",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia

T2 - A follow-up of the Eastern Cooperative Oncology Group E3A98 trial

AU - Gertz, Morie A.

AU - Abonour, Rafat

AU - Heffner, Leonard T.

AU - Greipp, Philip R.

AU - Uno, Hajime

AU - Rajkumar, S. V.

PY - 2009/12

Y1 - 2009/12

N2 - Waldenström macroglobulinaemia is a low-grade, lymphoplasmacytic lymphoma that is responsive to rituximab. We report the role of a minor response in predicting overall outcomes. We extended follow-up of a previously described cohort (n = 69) treated with 4 weekly doses of rituximab and observed durable responses (median time to progression, 30 months; 5-year survival rate, 66%). Patients achieving a minor response [25-50% immunoglobulin M (IgM) reduction] appeared to do as well as those achieving an objective response (>50% IgM reduction), which suggests that more aggressive or intensive therapy for minor responders is not required. Future studies of Waldenström macroglobulinaemia should report minor responses because they are associated with clinically meaningful benefits. This trial was registered at http://www.clinicaltrials.gov as #NCT00005609.

AB - Waldenström macroglobulinaemia is a low-grade, lymphoplasmacytic lymphoma that is responsive to rituximab. We report the role of a minor response in predicting overall outcomes. We extended follow-up of a previously described cohort (n = 69) treated with 4 weekly doses of rituximab and observed durable responses (median time to progression, 30 months; 5-year survival rate, 66%). Patients achieving a minor response [25-50% immunoglobulin M (IgM) reduction] appeared to do as well as those achieving an objective response (>50% IgM reduction), which suggests that more aggressive or intensive therapy for minor responders is not required. Future studies of Waldenström macroglobulinaemia should report minor responses because they are associated with clinically meaningful benefits. This trial was registered at http://www.clinicaltrials.gov as #NCT00005609.

KW - Lymphoplasmacytic lymphoma

KW - Monoclonal IgM protein

KW - Rituximab

KW - Waldenström macroglobulinaemia

UR - http://www.scopus.com/inward/record.url?scp=70449356982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449356982&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07892.x

DO - 10.1111/j.1365-2141.2009.07892.x

M3 - Article

VL - 147

SP - 677

EP - 680

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -